NeuroMetrix, Inc. (NURO): Price and Financial Metrics


NeuroMetrix, Inc. (NURO): $7.34

-1.01 (-12.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NURO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 509

in industry

NURO POWR Grades


  • Growth is the dimension where NURO ranks best; there it ranks ahead of 92.15% of US stocks.
  • NURO's strongest trending metric is Value; it's been moving down over the last 52 weeks.
  • NURO's current lowest rank is in the Stability metric (where it is better than 3.72% of US stocks).

NURO Stock Summary

  • With a market capitalization of $47,001,373, NeuroMetrix Inc has a greater market value than just 7.11% of US stocks.
  • With a year-over-year growth in debt of -37.42%, NeuroMetrix Inc's debt growth rate surpasses merely 14.02% of about US stocks.
  • The volatility of NeuroMetrix Inc's share price is greater than that of 99.46% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to NURO, based on their financial statements, market capitalization, and price volatility, are VYNE, MBII, AMSC, FLDM, and BIGC.
  • NURO's SEC filings can be seen here. And to visit NeuroMetrix Inc's official web site, go to www.neurometrix.com.

NURO Valuation Summary

  • In comparison to the median Healthcare stock, NURO's price/earnings ratio is 256.71% lower, now standing at -57.2.
  • NURO's price/sales ratio has moved up 0.9 over the prior 208 months.
  • NURO's price/sales ratio has moved up 0.9 over the prior 208 months.

Below are key valuation metrics over time for NURO.

Stock Date P/S P/B P/E EV/EBIT
NURO 2021-08-31 8.2 7.6 -57.2 -50.8
NURO 2021-08-30 9.5 8.8 -66.5 -60.1
NURO 2021-08-27 11.3 10.5 -79.1 -72.7
NURO 2021-08-26 6.8 6.3 -47.8 -41.3
NURO 2021-08-25 7.1 6.6 -49.9 -43.4
NURO 2021-08-24 7.8 7.2 -54.3 -47.8

NURO Growth Metrics

  • Its year over year cash and equivalents growth rate is now at 82.68%.
  • Its 4 year net income to common stockholders growth rate is now at 42.19%.
  • The 2 year cash and equivalents growth rate now stands at -53.81%.
Over the past 15 months, NURO's revenue has gone down $106,692.

The table below shows NURO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 8.214931 -0.803839 -1.174247
2021-03-31 7.361411 -1.337473 -1.494607
2020-12-31 7.377975 -2.066861 -2.092195
2020-09-30 7.275146 -2.409208 -2.823158
2020-06-30 7.326919 -3.630732 -3.970645
2020-03-31 8.321623 -4.804797 -6.480892

NURO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NURO has a Quality Grade of C, ranking ahead of 40.25% of graded US stocks.
  • NURO's asset turnover comes in at 0.944 -- ranking 22nd of 186 Medical Equipment stocks.
  • BLFS, NVNO, and STAA are the stocks whose asset turnover ratios are most correlated with NURO.

The table below shows NURO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.944 0.739 -0.690
2021-03-31 0.902 0.717 -0.828
2020-12-31 0.948 0.712 -1.087
2020-09-30 0.969 0.684 -1.415
2020-06-30 0.970 0.635 -1.936
2020-03-31 1.027 0.360 -3.126

NURO Stock Price Chart Interactive Chart >

Price chart for NURO

NURO Price/Volume Stats

Current price $7.34 52-week high $38.75
Prev. close $8.35 52-week low $1.47
Day low $7.15 Volume 905,800
Day high $8.11 Avg. volume 3,505,149
50-day MA $10.68 Dividend yield N/A
200-day MA $6.40 Market Cap 41.32M

NeuroMetrix, Inc. (NURO) Company Bio


NeuroMetrix Inc. is a medical device company that designs, develops and sells proprietary products used to diagnose neuropathies. The Company's neuropathy diagnostic system provides primary care and specialist physicians objective information that aids in the diagnosis of neuropathies at the point of service.


NURO Latest News Stream


Event/Time News Detail
Loading, please wait...

NURO Latest Social Stream


Loading social stream, please wait...

View Full NURO Social Stream

Latest NURO News From Around the Web

Below are the latest news stories about NeuroMetrix Inc that investors may wish to consider to help them evaluate NURO as an investment opportunity.

NeuroMetrix Reports Q3 2021 Financial Results

WOBURN, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2021. The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. Highlights: Revenue of $2.1 million was up slightly from Q3 2020. Gross margin on revenue was $1.4 million, a 70.0% gross margin rate. This was a decrease of 3.6 percentage points from $1.5 m

Yahoo | October 21, 2021

NeuroMetrix Names Strategic Growth Executive, Susan M. Bell, RN, BN, as Senior Vice President of Population Health & Value Based Care

WOBURN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Susan M. Bell as Senior Vice President, Population Health & Value Based Care. Ms. Bell will be responsible for growing the Company's DPNCheck® business with a primary focus on the Medicare Advantage population, and more broadly, expanding the Company's footprint in the value-based healthcare market. DPNCheck is a widely used point-of-care test that provides physicians with fast

Yahoo | October 20, 2021

Those who invested in NeuroMetrix (NASDAQ:NURO) a year ago are up 453%

Some NeuroMetrix, Inc. ( NASDAQ:NURO ) shareholders are probably rather concerned to see the share price fall 55% over...

Yahoo | October 20, 2021

NeuroMetrix, Inc. Announces Date for Third Quarter 2021 Financial Results Conference Call

WOBURN, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 third quarter financial results before the opening of the market on October 21, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on October 21, 2021 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation

Yahoo | October 14, 2021

28 Stocks Moving In Thursday's Mid-Day Session

Gainers Camber Energy, Inc.. (NYSE: CEI) jumped 44.2% to $1.3102 after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial statements of Viking. Paltalk, Inc. (NASDAQ: PALT) shares jumped 40.1% to $9.71 after dropping over 15% on Wednesday. Paltalk’s recent filing showed registration for $50 million mixed securities shelf offering. Merus N.V. (NASDAQ: MRUS) surged 38.7% to $27.74 as the company presented early clinical data on MCLA-158 and preclinical data on zenocutu

Yahoo | October 7, 2021

Read More 'NURO' Stories Here

NURO Price Returns

1-mo -36.59%
3-mo -59.56%
6-mo 144.67%
1-year 347.56%
3-year -36.72%
5-year -93.40%
YTD 132.28%
2020 -26.51%
2019 -43.42%
2018 -56.04%
2017 -70.79%
2016 -62.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.771 seconds.